| __timestamp | Eli Lilly and Company | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 14993000000 |
| Thursday, January 1, 2015 | 6533000000 | 14247000000 |
| Friday, January 1, 2016 | 6452000000 | 14192000000 |
| Sunday, January 1, 2017 | 6588100000 | 14997000000 |
| Monday, January 1, 2018 | 5975100000 | 16471000000 |
| Tuesday, January 1, 2019 | 6213800000 | 14369000000 |
| Wednesday, January 1, 2020 | 6121200000 | 14197000000 |
| Friday, January 1, 2021 | 6431600000 | 14886000000 |
| Saturday, January 1, 2022 | 6440400000 | 14253000000 |
| Sunday, January 1, 2023 | 6941200000 | 12489000000 |
| Monday, January 1, 2024 | 8593800000 | 12566000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial for maintaining profitability. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants, Eli Lilly and Company and Novartis AG, from 2014 to 2023. Over this period, Novartis consistently reported higher SG&A expenses, averaging around 14.5 billion USD annually, nearly double that of Eli Lilly's average of 6.4 billion USD. However, a notable shift occurred in 2023 when Eli Lilly's expenses surged by approximately 8%, reaching their highest at 6.9 billion USD, while Novartis saw a significant reduction of 16%, dropping to 12.5 billion USD. This trend highlights the dynamic nature of cost management strategies within the sector, reflecting broader shifts in corporate priorities and market conditions.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Novartis AG vs Insmed Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Novartis AG vs Walgreens Boots Alliance, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Novartis AG and ADMA Biologics, Inc.
Selling, General, and Administrative Costs: Novartis AG vs Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Evotec SE